Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680017 | 0.93 | PDE1B (0.41) | PTGS2PTGS1PDE1BPDE2APDE4D | |
| SCHEMBL676380 | 0.88 | PDE1B (0.49) | PTGS2PTGS1PDE1BPDE2APDE4D | |
| SCHEMBL15943410 | 0.88 | PDE1B (0.47) | PTGS2PTGS1PDE1BPDE2APDE4D | |
| SCHEMBL680009 | 0.86 | PDE1B (0.37) | PDE1BPDE2APDE4DGRM2HPGD | |
| SCHEMBL674937 | 0.86 | PDE1B (0.37) | PDE1BPDE2APDE4DGRM2HPGD | |
| SCHEMBL674429 | 0.86 | ALDH1A1 (0.43) | GRM2 | |
| SCHEMBL676359 | 0.83 | PDE1B (0.42) | PDE1BPDE2AGRM2HPGDPDE1A | |
| SCHEMBL676325 | 0.82 | DPP4 (0.37) | PTGS2PTGS1PDE1BPDE2AGRM2 | |
| SCHEMBL678934 | 0.81 | PDE1B (0.40) | PDE1BPDE2APDE4DGRM2HPGD | |
| SCHEMBL676517 | 0.81 | PDE1B (0.54) | PDE1BPDE2APDE4DGRM2PDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487527-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150119370-A1 | Organic Compounds | LI PENG (US) | 2015-04-30 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2367430-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2367430-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
| EP-2367430-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065152-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | PTGS2 553/4885PTGS1 799/4885PDE1B 4855/4885 |
| US-20150119370-A1 | Organic Compounds | CYP2C19, CYP2C9, CYP3A43 | PTGS2 927/4885PTGS1 1124/4885PDE1B 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.